Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03246685
Title Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Biothera

head and neck squamous cell carcinoma


Pembrolizumab + PGG beta-glucan

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.